IRTC

iRhythm Technologies Inc

Add to Watchlist

Advanced Chart

140.080

+3.31(2.420%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

142.560

Open

136.770

VWAP

140.55

Vol

417.00K

Mkt Cap

4.47B

Low

136.320

Amount

58.61M

EV/EBITDA(TTM)

Total Shares

31.10M

4.49B

EV/OCF(TTM)

94.54

P/S(TTM)

6.93

iRhythm Technologies, Inc. is a digital health care company, which creates solutions that detect, predict, and prevent disease. The Company designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. It offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. It offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services (Zio Services), using its Zio Systems. The Zio Monitor System is a prescription-only, remote ECG monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

173.94M

+17.49%

-0.474

-22.23%

173.19M

+17.39%

-0.307

-75.66%

189.89M

+15.56%

0.037

+268%

Estimates Revision

The market is revising Upward the revenue expectations for iRhythm Technologies, Inc. (IRTC) for FY2025, with the revenue forecasts being adjusted by 1.88% over the past three months. During the same period, the stock price has changed by 29.00%.

Revenue Estimates for FY2025

Revise Upward

+1.88%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.53%

In Past 3 Month

Stock Price

Go Up

+29.00%

In Past 3 Month

9 Analyst Rating

7.53% Upside

Wall Street analysts forecast IRTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRTC is 150.63 USD with a low forecast of 130.00 USD and a high forecast of 167.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

7.53% Upside

Current: 140.080

Low

130.00

Averages

150.63

High

167.00

7.53% Upside

Current: 140.080

Low

130.00

Averages

150.63

High

167.00

Morgan Stanley

Kallum Titchmarsh

Overweight

downgrade

$160 -> $147

2025-07-15

Reason

Morgan Stanley

Kallum Titchmarsh

Price Target

$160 -> $147

2025-07-15

downgrade

Overweight

Reason

Morgan Stanley analyst Kallum Titchmarsh lowered the firm's price target on iRhythm to $147 from $160 and keeps an Overweight rating on the shares.The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.

BTIG

Marie Thibault

Buy

maintain

$165

2025-07-14

Reason

BTIG

Marie Thibault

Price Target

$165

2025-07-14

maintain

Buy

Reason

BTIG analyst Marie Thibault reiterated a Buy rating and $165 price target on iRhythm Technologies after the Centers for Medicare & Medicaid published its CY26 Physician Fee Schedule Proposal, under which payment rates would be flat for long-term monitoring mobile cardiac telemetry reimbursement would get a low-single digit \"boost.\" The proposed payment rate for CPT code 93229 for Zio AT mobile cardiac telemetry in the San Francisco geography was set at $1,083, a 2.7% boost compared to CY25, the analyst tells investors in a research note. The firm said this is a positive surprise since this code has been subject to relatively large cuts in recent years, adding that while the proposed rates are still subject to change, it does not make any changes to its estimates at this time.

BTIG

Marie Thibault

Buy

maintain

$140 -> $165

2025-06-21

Reason

BTIG

Marie Thibault

Price Target

$140 -> $165

2025-06-21

maintain

Buy

Reason

BTIG analyst Marie Thibault raised the firm's price target on iRhythm to $165 from $140 and keeps a Buy rating on the shares after the firm hosted investor meetings with its management team. The discussions focused on the company's recent market share gains in the Zio AT segment, the competitive landscape, the asymptomatic opportunity with innovative channel partners, and remediation efforts regarding the warning letter and Form 483 observations, the analyst tells investors in a research note. The tone of these meetings was positive and the management was upbeat, remaining confident that the recent momentum can be sustained for the rest of the year and beyond, the firm added.

Morgan Stanley

NULL

Overweight

upgrade

$130 -> $160

2025-06-10

Reason

Morgan Stanley

Price Target

$130 -> $160

2025-06-10

upgrade

NULL

Overweight

Reason

Morgan Stanley raised the firm's price target on iRhythm to $160 from $130 and keeps an Overweight rating on the shares. The firm says a a quick look at iRhythm's Q2 app downloads points to upside risk versus Street estimates. The majority of Zio patches driving the company's Q2 revenue have already been prescribed, providing a good read of the quarter, the analyst tells investors in a research note. Downloads of the MyZio app in Q2 totaled 171,169, up 74% years-over-year and up 36% versus Q1, Morgan Stanley notes. It continues to believe iRhythm is an attractive asset to own both nearer and longer term.

Citi

Joanne Wuensch

NULL -> Buy

maintain

$130 -> $167

2025-05-22

Reason

Citi

Joanne Wuensch

Price Target

$130 -> $167

2025-05-22

maintain

NULL -> Buy

Reason

Citi analyst Joanne Wuensch raised the firm's price target on iRhythm to $167 from $130 and keeps a Buy rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note.

Goldman Sachs

David Roman

Hold

Maintains

$91 → $124

2025-02-24

Reason

Goldman Sachs

David Roman

Price Target

$91 → $124

2025-02-24

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for iRhythm Technologies Inc (IRTC.O) is -110.18, compared to its 5-year average forward P/E of -56.97. For a more detailed relative valuation and DCF analysis to assess iRhythm Technologies Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-56.97

Current PE

-110.18

Overvalued PE

-10.13

Undervalued PE

-103.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

168.36

Current EV/EBITDA

74.92

Overvalued EV/EBITDA

1076.40

Undervalued EV/EBITDA

-739.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

8.06

Current PS

6.07

Overvalued PS

12.76

Undervalued PS

3.35

Financials

Annual

Quarterly

FY2025Q1

YoY :

+20.27%

158.68M

Total Revenue

FY2025Q1

YoY :

-16.70%

-31.77M

Operating Profit

FY2025Q1

YoY :

-32.77%

-30.70M

Net Income after Tax

FY2025Q1

YoY :

-34.01%

-0.97

EPS - Diluted

FY2025Q1

YoY :

-71.99%

-17.31M

Free Cash Flow

FY2025Q1

YoY :

+3.75%

68.83

Gross Profit Margin - %

FY2025Q1

YoY :

-99.23%

-0.17

FCF Margin - %

FY2025Q1

YoY :

-44.09%

-19.35

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

2.5M

USD

3-6

Months

1.0M

USD

6-9

Months

7.2M

USD

0-12

Months

1.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

500.9K

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 281.11% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

294.1K

Volume

6-9

Months

77.2K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

56.8K

Volume

Months

6-9

2.1M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

2.5M

USD

3-6

Months

1.0M

USD

6-9

Months

7.2M

USD

0-12

Months

1.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

500.9K

USD

Months

IRTC News & Events

Events Timeline

2025-07-07 (ET)

2025-07-07

08:37:15

iRhythm appoints Karen McGinnis, Kevin O'Boyle to board of directors

2025-06-23 (ET)

2025-06-23

08:45:04

iRhythm announces results from two large-scale real-world studies at ADA 2025

2025-05-01 (ET)

2025-05-01

16:16:55

iRhythm sees FY25 revenue $690M-$700M, consensus $681.71M

News

3.5

07-15Newsfilter

Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity

5.0

07-07Newsfilter

iRhythm Technologies Announces Board Member Retirements and New Director Appointments

9.0

06-23NASDAQ.COM

iRhythm Technologies Reveals New Insights on Cardiac Arrhythmias in Type 2 Diabetes Patients at ADA 2025

People Also Watch

Algonquin Power & Utilities Corp

Rush Street Interactive Inc

Resideo Technologies Inc

FAQ

What is iRhythm Technologies Inc (IRTC) stock price today?

The current price of IRTC is 140.08 USD — it has increased 2.42 % in the last trading day.

IRTC

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

IRTC News & Events

Events Timeline

News

People Also Watch

FAQ

What is iRhythm Technologies Inc (IRTC) stock price today?

What is iRhythm Technologies Inc (IRTC)'s business?

What is the price predicton of IRTC Stock?

What is iRhythm Technologies Inc (IRTC)'s revenue for the last quarter?

What is iRhythm Technologies Inc (IRTC)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for iRhythm Technologies Inc (IRTC)'s fundamentals?

How many employees does iRhythm Technologies Inc (IRTC). have?

What is iRhythm Technologies Inc (IRTC) market cap?